Pinoxacin Hydrochloride, a category 1.1 drug, is a DPP-4 inhibitor class of oral hypoglycemic agents used to enhance the function of endogenous insulin for improving glycemic control and islet beta-cells function.
During the company’s pre-clinical research, DPP-4 inhibitors have shown potent in-vitro and in-vivo activities, good selection profile, great stability and controllable quality, as well as better tolerance, with long-term administration showing a protective effect on pancreatic beta-cells.
Pinoxacin Hydrochloride has good pharmacokinetic characteristics, high oral bioavailability, quick absorption, rapid onset and a longer duration, claims the company.
The company is expecting to begin the Phase I clinical study in the first half of 2013.
Sihuan Pharmaceutical chairman and CEO Dr Che Fengsheng said, "We believe Pinoxacin Hydrochloride will provide physicians and patients with better treatment options after its launch, and will mark an important milestone for Sihuan Pharmaceutical as it enters into another major therapeutic area."